Aveo Pharmaceuticals Inc
F:VPA1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
VPA1's latest stock split occurred on Feb 20, 2020
The company executed a 1-for-10 stock split, meaning that for every 10 shares held, investors received 1 new share.
Before the split, VPA1 traded at 0.4999 per share. Afterward, the share price was about 4.777.
The adjusted shares began trading on Feb 20, 2020. This was the only stock split in VPA1's history.
Global
Stock Splits Monitor
| Date | Company | Split | Pre-Split Price | Post-Split Price | |
|---|---|---|---|---|---|
|
Apr 24, 2026
|
|
Cue Biopharma Inc
NASDAQ:CUE
|
1-for-30
/30
|
0.5542 16.626 USD | 17.695 17.695 USD |
|
Apr 24, 2026
|
|
Medical Data Vision Co Ltd
TSE:3902
|
2-for-7253607
/3626803.5
|
1684 1684 JPY | N/A |
|
Apr 24, 2026
|
E
|
ESGL Holdings Ltd
NASDAQ:ESGL
|
1-for-3
/3
|
2.35 7.05 USD | 2.93 2.93 USD |
|
Apr 24, 2026
|
|
Metro Mining Ltd
ASX:MMI
|
1-for-20
/20
|
0.067 1.34 AUD | 1.3 1.3 AUD |
|
Apr 24, 2026
|
L
|
La Comer SAB de CV
OTC:LCMRF
|
115-for-114
x1.0087719298246
|
2.4715 2.4341 USD | 2.45 2.45 USD |
CUE
3902
MMI
Aveo Pharmaceuticals Inc
Glance View
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. The company is headquartered in Boston, Massachusetts and currently employs 114 full-time employees. The company went IPO on 2010-03-12. The firm is focused on delivering medicines for patients with cancer. The Company’s commercial product include FOTIVDA (tivozanib), which is an oral, vascular endothelial growth factor receptor (VEGFR) and tyrosine kinase inhibitor (TKI). The firm markets FOTIVDA (tivozanib) in the United States for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. The company also develops FOTIVDA in immuno-oncology combinations in refractory RCC and other indications and has several other investigational programs in clinical development. The Company’s pipeline of product candidates includes ficlatuzumab, AV-380, AV-203 and AV-353. Its ficlatuzumab is a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor (HGF).
